Pengfei Jin, Xiling Guo, Jin-Bo Gou, Lihua Hou et al.
Background: People over 60 have been found to develop less protection after two doses of inactivated COVID-19 vaccines than younger people. Heterologous immunisation could potentially induce more robust immune responses compared to homologous immunisation. We aimed to assess the immunogenicity and s...
Rong Tang, Hui Zheng, Busen Wang, Jin-Bo Gou et al.
Background: This study aimed to evaluate the safety and immunogenicity of aerosolised Ad5-nCoV or intramuscular Ad5-nCoV or inactivated COVID-19 vaccine CoronaVac given as the second booster. Methods: This is an ongoing, randomized, open-label, parallel-controlled phase 4 trial involving healthy par...
Pengfei Jin, Jingxin Li, Xiling Guo, Jin-Bo Gou et al.
Abstract Importance People over 60 developed less protection after two doses of inactivated COVID-19 vaccine than younger people. Heterologous vaccination might provide greater immunity and protection against variants of concern. Objective To assess the safety and immunogenicity of a heterologous im...
Jingxin Li, Shipo Wu, Xiling Guo, Rong Tang et al.
Background: A third dose of homologous or heterologous COVID-19 vaccine is suggested to use in individuals who were previously primed with two doses of inactivated COVID-19 vaccine. Methods: We conducted a randomised, open-label, parallel-controlled trial to evaluate the safety and immunogenicity of...